Printable version
Collateral Formulary Access Impact in the Sleep Disorder Class due to Patent Loss for Ambien (PDF 314KB)
Archives
December 2007: Lack of Impact from Two Key Generics in the Anti-depressant Formulary Market
October 2007: Formulary Position Differences between Commercial and Medicare Plans
September 2007: Impact of Patent Loss for Zocor on the Statin Marketplace
Welcome!
Fingertip Formulary Insights™ is a series of ongoing reports that analyze various important aspects of the managed care marketplace. As always, we welcome your feedback. We hope you find this report informative and we welcome your suggestions for future topics.
This month's featured article: Collateral Formulary Access Impact in the Sleep Disorder Class due to Patent Loss for Ambien
Executive Summary
While the impact on formulary access for a brand product losing patent protection is typically rapid and clear cut, the broader impact on remaining branded competitors within the therapeutic drug class is less clear. With the availability of a lower cost generic, plans may have greater flexibility to move existing brands to higher tiers or place new access restrictions, such as prior authorization or step therapy.